New Key Statistics Module, Z-Score and F-Score
OTCPK:SUDFF Key Ratios
| Market Cap $ M | 12.07 |
| Enterprise Value $ M | 12.81 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 13.18 |
| Price/Sales | -- |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -- |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | 16.50 |
| 5-y EBITDA Growth Rate % | 34.40 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -17.06 |
| EV-to-EBITDA | -17.14 |
| PEG | -- |
| Shares Outstanding M | 480.92 |
| Net Margin (%) | -48,588.89 |
| Operating Margin % | -60,061.11 |
| Pre-tax Margin (%) | -48,588.89 |
| Quick Ratio | 6.44 |
| Current Ratio | 6.44 |
| ROA % (ttm) | -108.94 |
| ROE % (ttm) | -144.63 |
| ROIC % (ttm) | -2,671.58 |
| Dividend Yield % | -- |
| Altman Z-Score | 33.25 |
SUDFF Number of Guru Trades
SUDFF Volume of Guru Trades
Gurus Latest Trades with OTCPK:SUDFF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
OTCPK:SUDFF is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Arovella Therapeutics Ltd Insider Transactions
No Available Data
News about OTCPK:SUDFF
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers